Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Brief description of study

Testing for elevated Lipoprotein(a) [Lp(a)] very rarely occurs in everyday clinical practice, despite its establishment as an important genetic cardiovascular (CV) risk factor. The 2018 American College of Cardiology/American Heart Association Cholesterol Guideline suggests individuals with Lp(a) levels =125 nmol/L (or =50 mg/dL) are at high risk.

Data relevant to the prevalence of patients with elevated Lp(a) in patients with established ASCVD, especially by country/region, is still sparse.

The purpose of this study is to characterize the distribution of Lp(a) levels among patients with a history of ASCVD as defined by their medical history and is 2-fold:

  • Evaluate the distribution of Lp(a) value in the overall patients with documented history of myocardial infarction (MI) and/or percutaneous coronary intervention (PCI).
  • Evaluate the distribution of Lp(a) value in patients with documented history of MI and/or PCI by demographics and regions.

  • Clinical Study Identifier: s22-00421
    Principal Investigator: Howard Weintraub.
    Other Investigator: Arthur Z Schwartzbard.

    If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

    Contact the research team to learn more about this study.

    By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.